Celcuity (CELC) Retained Earnings (2016 - 2026)
Celcuity's (CELC) quarterly Retained Earnings came in at -$448.9 million in Q4 2025, down 65.12% YoY from -$1.3 billion in Q4 2024, and down 12.81% on a QoQ basis from -$397.9 million in Q3 2025.
Celcuity (CELC) Retained Earnings (2016 - 2026) Analysis & Trends
Celcuity (CELC) has 10 years of Retained Earnings data on file, last reported at -$448.9 million in Q4 2025.
- Quarterly Retained Earnings fell 65.12% year-over-year to -$448.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$448.9 million (down 65.12% YoY) and the FY2025 annual result came in at -$448.9 million, down 65.12% from the prior year.
- Retained Earnings eased to -$448.9 million in Q4 2025, from -$397.9 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $398.5 million in Q2 2025 to a low of -$448.9 million in Q4 2025.
- A 5-year average of -$57.6 million and a median of -$79.3 million in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2021 — Retained Earnings tumbled 231.05% — and 2022, when it surged 511.33%.
- Tracing CELC's Retained Earnings over 5 years: stood at -$55.9 million in 2021, then surged by 511.33% to $230.0 million in 2022, then plunged by 169.58% to -$160.1 million in 2023, then slumped by 69.83% to -$271.9 million in 2024, then tumbled by 65.12% to -$448.9 million in 2025.
- The last three Retained Earnings figures came in at -$448.9 million (Q4 2025), -$397.9 million (Q3 2025), and $398.5 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Celcuity | 4.50 Bn | 4.50 Bn | - | -580.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -580.60 Mn |
| Dec 31, 2025 | -448.90 Mn |
| Sep 30, 2025 | -397.92 Mn |
| Jun 30, 2025 | 398.46 Mn |
| Mar 31, 2025 | -308.85 Mn |
| Dec 31, 2024 | -271.86 Mn |
| Sep 30, 2024 | 384.87 Mn |
| Jun 30, 2024 | -205.41 Mn |
| Mar 31, 2024 | -181.69 Mn |
| Dec 31, 2023 | -160.08 Mn |
| Sep 30, 2023 | 234.10 Mn |
| Jun 30, 2023 | -122.82 Mn |
| Mar 31, 2023 | -108.24 Mn |
| Dec 31, 2022 | 230.05 Mn |
| Sep 30, 2022 | -84.72 Mn |
| Jun 30, 2022 | -73.82 Mn |
| Mar 31, 2022 | -63.86 Mn |
| Dec 31, 2021 | -55.93 Mn |
| Sep 30, 2021 | -49.17 Mn |
| Jun 30, 2021 | 70.17 Mn |